文献速递白血病造血干细胞移植与细胞治疗

优化儿童晚期骨髓复发B细胞急性淋巴细胞白血病的分层:精细反应分类与遗传学整合

Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics.
PubMed 文献 · J Clin Oncol · 2019-10-23

该研究在ALL-REZ BFM 2002试验/登记中纳入413例晚期骨髓复发B细胞前体急性淋巴细胞白血病患儿,中位随访9.4年,评估诱导后及移植前MRD反应与遗传学异常对预后的影响。结果显示基于MRD的分层治疗可获得良好生存,TP53改变是所有MRD反应组中唯一独立预后不良的遗传标志。

要点

  • 诱导后MRD≥10^-2者EFS降至56%,早期无反应者(原始细胞≥25%)EFS仅22%。
  • 移植前MRD≥10^-3的晚期无反应者仍可达EFS 50%、OS 63%,支持行allo-HSCT。
  • TP53改变(频率8%)在所有MRD反应亚组中均为独立不良预后因素。

核心结论

  • 基于诱导后MRD的治疗分层可使晚期复发BCP-ALL患儿获得优异生存。
  • TP53改变可作为晚期复发BCP-ALL所有MRD反应组的新型遗传高危标志。
  • 早期和晚期无反应者应被视为未来试验中的事件。

研究设计与样本

  • ALL-REZ BFM 2002试验/登记(NCT00114348)纳入413例晚期骨髓复发BCP-ALL患儿,中位随访9.4年。
  • 在诱导治疗后及复发治疗至allo-HSCT期间多个时间点评估MRD。
  • 诱导反应差(MRD≥10^-3)者指示行allo-HSCT。

主要发现

  • 诱导反应良好(MRD<10^-3)与差者EFS分别为72%和65%,OS分别为82%和74%。
  • 诱导后原始细胞≥25%的早期无反应者预后最差,EFS为22%。
  • 移植前MRD≥10^-3的晚期无反应者EFS为50%、OS为63%。
  • TP53改变频率8%,是任何MRD反应亚组中唯一具独立预后价值的遗传改变。

关键数值与推荐

  • 诱导后MRD≥10^-3定义为反应差并指示行allo-HSCT。
  • 诱导后MRD≥10^-2者EFS为56%。
  • 诱导后原始细胞≥25%定义为早期无反应者,EFS为22%。
  • 移植前MRD≥10^-3定义为晚期无反应者,EFS 50%、OS 63%。
  • TP53改变频率为8%。

临床怎么用

  • 对晚期骨髓复发BCP-ALL患儿应依据诱导后MRD水平进行移植决策分层。
  • 诱导后MRD≥10^-2或原始细胞≥25%者预后差,可考虑在诱导后直接强化治疗。
  • 移植前MRD≥10^-3者仍可从allo-HSCT获益,不应仅因MRD阳性而放弃移植。
  • 所有MRD反应组均应检测TP53改变以识别高危患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Minimal residual disease (MRD) helps to accurately assess when children with late bone marrow relapses of B-cell precursor (BCP) acute lymphoblastic leukemia (ALL) will benefit from allogeneic hematopoietic stem-cell transplantation (allo-HSCT). More detailed dissection of MRD response heterogeneity and the specific genetic aberrations could improve current practice. PATIENTS AND METHODS: MRD was assessed after induction treatment and at different times during relapse treatment until allo-HSCT (indicated in poor responders to induction; MRD ≥ 10-3) for patients being treated for late BCP-ALL bone marrow relapses (n = 413; median follow-up, 9.4 years) in the ALL-REZ BFM 2002 trial/registry (ClinicalTrials.gov identifier: NCT00114348). RESULTS: Patients with both good (MRD < 10-3) and poor responses to induction treatment reached excellent event-free survival (EFS; 72% v 65%) and overall survival (OS; 82% v 74%). Patients with MRD of 10-2 or greater after induction had reduced EFS (56%), and their MRD persisted until allo-HSCT more frequently than it did in patients with MRD of 10-3 or greater to less than 10-2 (P = .037). Patients with 25% or more leukemic blasts after induction (early nonresponders) had the poorest prognosis (EFS, 22%). Interestingly, patients with MRD of 10-3 or greater before allo-HSCT (late nonresponders) still had an EFS of 50% and OS of 63%, which in principle justifies allo-HSCT in these patients. From a panel of selected candidate genes, TP53 alterations (frequency, 8%) were the only genetic alteration with independent prognostic value in any MRD-based response subgroup. CONCLUSION: After induction treatment, MRD-based treatment stratification resulted in excellent survival in patients with late relapsed BCP-ALL. Prognosis could be further improved in very poor responders by intensifying treatment directly after induction. TP53 alterations can be defined as a novel genetic high-risk marker in all MRD response groups in late relapsed BCP-ALL. Here we identified early and late nonresponders to be considered as events in future trials.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Eckert C, Groeneveld-Krentz S, Kirschner-Schwabe R, et al. Improving Stratification for Children With Late Bone Marrow B-Cell Acute Lymphoblastic Leukemia Relapses With Refined Response Classification and Integration of Genetics. J Clin Oncol. 2019. PMID: 31644328. doi:10.1200/JCO.19.01694

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。